Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and
safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.